Regulus Therapeutics Inc. (RGLS)
NASDAQ: RGLS · Real-Time Price · USD
1.750
+0.020 (1.14%)
At close: Apr 1, 2025, 4:00 PM
1.730
-0.020 (-1.13%)
After-hours: Apr 1, 2025, 4:40 PM EDT

Company Description

Regulus Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States.

The company develops farabursen, an anti-miR oligonucleotide targeting miR-17 in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease.

It is also developing a pipeline of preclinical drug products for target organ-selective delivery strategies.

The company has a license and collaboration agreement with Alnylam Pharmaceuticals, Inc. and Ionis Pharmaceuticals, Inc. to develop, manufacture, and commercialize products covered by the licensed patent rights for use in microRNA compounds.

Regulus Therapeutics Inc. was incorporated in 2007 and is headquartered in San Diego, California.

Regulus Therapeutics Inc.
Regulus Therapeutics logo
Country United States
Founded 2007
IPO Date Oct 4, 2012
Industry Biotechnology
Sector Healthcare
Employees 34
CEO Joseph Hagan

Contact Details

Address:
4224 Campus Point Court, Suite 210
San Diego, California 92121
United States
Phone 858 202 6300
Website regulusrx.com

Stock Details

Ticker Symbol RGLS
Exchange NASDAQ
Stock Type Common Stock
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001505512
CUSIP Number 75915K309
ISIN Number US75915K3095
Employer ID 26-4738379
SIC Code 2834

Key Executives

Name Position
Joseph P. Hagan M.B.A. Chief Executive Officer and Director
Crispina Calsada CPA Chief Financial Officer
Christopher Ray Aker J.D. Senior Vice President, General Counsel and Corporate Secretary
Dr. Preston S. Klassen M.D., M.H.S. President, Head of Research and Development and Director
Daniel J. Penksa Vice President of Finance and Controller
Dr. Claire Susan Padgett M.S., M.T., Ph.D. Senior Vice President of Clinical Operations
Dr. Rekha Garg M.D., M.S. Chief Medical Officer
Edmund Lee Ph.D. Vice President of Translational Medicine

Latest SEC Filings

Date Type Title
Mar 27, 2025 8-K Current Report
Mar 13, 2025 10-K Annual Report
Mar 13, 2025 8-K Current Report
Mar 4, 2025 8-K Current Report
Jan 30, 2025 S-8 Securities to be offered to employees in employee benefit plans
Nov 14, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Nov 14, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Nov 14, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Nov 12, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Nov 8, 2024 SC 13G Statement of acquisition of beneficial ownership by individuals